Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Flexible With Accelerated Approval Evidence, Analysis Finds

Executive Summary

Attorneys Sasinowski and Varond write that in some cases weak clinical evidence on the surrogate endpoint was not a barrier, but strong findings on unmet need and rarity usually are necessary for accelerated approval.


Related Content

Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
FDA Central Review Likely For Novel Surrogate Endpoints
BIO Survey Seeks To Uncover Inconsistencies In Review Divisions
Biomarker Development Meeting May Help Expand Accelerated Approval
Biomarker Development Meeting May Help Expand Accelerated Approval
Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy
Biomarkers In Orphan Studies Still Need Past Experience, FDA Says
PDUFA V: Accelerated Approval Expansion May Outshine Rare Disease Improvements
Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
Synercid, Zyvox Drug Pricing Discourages Use, IDSA Rep Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts